Lilongwe — Malawi is spearheading large-scale pilot tests for the world's most advanced experimental malaria vaccine in a bid to prevent the disease that kills hundreds of thousands across Africa each year. After more than three decades in development and almost $1bn in investment, the cutting-edge trial will be rolled out in Malawi’s capital Lilongwe this week and in Kenya and Ghana next week. It aims to immunise 120,000 children aged 2 years and under to assess the effectiveness of the pilot vaccine and whether the delivery process is feasible. Four successive doses must be administered on a strict timetable for it to work. Trade-named Mosquirix, the drug has been developed by British pharmaceutical firm GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative. It passed previous scientific testing — including five years of clinical trials on 15,000 people in seven countries — and was approved for the pilot programme in 2015. Malaria episodes reduced by 40% in th...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now